This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

CHD (SAVE trial)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

2231 patients with asymptomatic left ventricular dysfunction (ejection fraction <= 40%) were randomised to:

  • oral captopril
  • placebo

Randomisation to drug or placebo took place 3-16 days post-MI (mean 11 days).

The SAVE trial demonstrated that:

  • captopril reduced mortality from all causes (20% vs. 25%)
  • captopril reduced mortality attributed to cardiovascular events (21% reduction in risk)

The investigators concluded that long-term therapy with captopril is indicated in patients who have left ventricular dysfunction post-myocardial infarction.

Reference:

  • (1) Pfeffer, MA. et al. (1992). Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 327(10), 669-77.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page